Biogen (BIIB), Johnson & Johnson (JNJ) and Amgen (AMGN) all have fast growing drugs about to become blockbusters this year.
Biogen Idec's Tecfidera is succeeding where Novartis and Sanofi struggled.
A collaboration pact with Eisai puts Biogen Idec right in the middle of a race to develop the first BACE inhibitor.
Biogen (BIIB) and Amgen (AMGN) are biotech heavyweights hitting new highs. Is one a better buy than the other?
Sangamo Biosciences shot up 20% today, but this may still be one to watch at a distance.See More Articles...